Usual Dose of Simvastatin Does Not Inhibit Plaque Progression and Lumen Loss at the Peri-Stent Reference Segments after Bare-Metal Stent Implantation: A Serial Intravascular Ultrasound Analysis by Hong, Young Joon et al.
Usual Dose of Simvastatin Does Not Inhibit Plaque
Progression and Lumen Loss at the Peri-Stent Reference
Segments after Bare-Metal Stent Implantation: A Serial
Intravascular Ultrasound Analysis
Young Joon Hong, Myung Ho Jeong, Yun Ha Choi, Eun Hye Ma, Jum Suk Ko, Min Goo Lee, Keun Ho Park, 
Doo Sun Sim, Nam Sik Yoon, Hyun Ju Youn, Kye Hun Kim, Hyung Wook Park, Ju Han Kim, Youngkeun Ahn,
Jeong Gwan Cho, Jong Chun Park, and Jung Chaee Kang
The Heart Center of Chonnam National University Hospital, Chonnam National University Research Institute of Medical
Sciences, Gwangju, Korea
DOI: 10.3904/kjim.2010.25.4.356
Background/Aims: The aim of this study was to assess the effects of a usual dose of simvastatin (20 mg/day) on
plaque regression and vascular remodeling at the peri-stent reference segments after bare-metal stent
implantation.
Methods: We retrospectively investigated serial intravascular ultrasound (IVUS) findings in 380 peri-stent
reference segments (184 proximal and 196 distal to the stent) in 196 patients (simvastatin group, n = 132 vs. non-
statin group, n = 64). Quantitative volumetric IVUS analysis was performed in 5-mm vessel segments proximal
and distal to the stent. 
Results: IVUS follow-up was performed at a mean of 9.4 months after stenting (range, 5 to 19 months). No
significant differences were observed in the changes in mean plaque plus media (P&M) area, mean lumen area,
and mean external elastic membrane (EEM) area from post-stenting to follow-up at both proximal and distal edges
between the simvastatin and non-statin group. Although lumen loss within the first 3 mm from each stent edge
was primarily due to an increase in P&M area rather than a change in EEM area, and lumen loss beyond 3 mm
from each stent edge was due to a combination of increased P&M area and decreased EEM area, no significant
differences in changes were observed in P&M, EEM, and lumen area at every 1-mm subsegment between the
simvastatin and non-statin group.
Conclusions: A usual dose of simvastatin does not inhibit plaque progression and lumen loss and does not affect
vascular remodeling in peri-stent reference segments in patients undergoing bare-metal stent implantation.
(Korean J Intern Med 2010;25:356-363)
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INTRODUCTION
Stent-edge and reference segment changes are
composed of the evolution of plaque and/or vessel area
changes, which can be visualized with intravascular
ultrasound (IVUS) before and after stenting [1-7]. Serial
IVUS examination of the plaque is very important because
it can offer a relatively exact mechanism of plaque
evolution. 
Recent trials have demonstrated that lipidlowering
therapy with statins improves clinical outcomes [8,9] and
reduces the progression of atherosclerosis [10]. The
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beneficial effects of statins, beyond their lipid-lowering
actions, mostly rely on their anti-inflammatory properties
[11]. Simvastatin has also been shown to inhibit smooth
muscle cell proliferations [12].
To the best of our knowledge, few data are available
regarding the effects of statins on plaque regression and
vascular remodeling in peri-stent reference segments. In
the present study, we assessed the effects of a usual dose
of simvastatin on plaque regression and vascular
remodeling in peri-stent reference segments after the use
of a bare-metal stent (BMS) using serial IVUS observat-
ions. Our hypothesis was that a usual dose of simvastatin
would not affect plaque regression and vascular
remodeling in peri-stent reference segments after BMS
implantation.
METHODS
Study population 
From January 2004 through December 2005, 196
patients who were treated with BMS implantation under
the guidance of IVUS at Chonnam National University
Hospital, Gwangju, Korea, were analyzed retrospectively.
The patients were divided into two groups: the
simvastatin group (n = 132) and the non-statin group (n =
64). For the simvastatin group, a 20 mg/day schedule of
simvastatin was introduced from just after stent
implantation through the follow-up period without
discontinuation. 
Among 392 peri-stent reference segments, 12 segments
proximal to the stent edge were excluded because of their
ostial location. Therefore, 380 peri-stent reference
segments were available for analysis, which consisted of
184 segments proximal to the stent edges and 196
segments distal to the stent edges. 
Cases of stent thrombosis, ostial stenting, far distal
stenting with < 2.5 mm of reference diameter, and
inadequate IVUS quality were excluded from the analysis.
The protocol was approved by the institutional review
board of Chonnam National University Hospital. Hospital
records of patients were reviewed to obtain clinical and
demographic variables. 
Laboratory analysis
In all patients, serum was collected before stent
implantation for measuring lipid profiles and high-
sensitivity C-reactive protein. All laboratory values were
measured after an overnight fast. The serum levels of total
cholesterol, low-density lipoprotein-cholesterol, high-
density lipoprotein-cholesterol, and triglycerides were
measured using standard enzymatic methods. High-
sensitivity cardiac C-reactive protein reagent (Beckman
Coulter, Fullerton, CA, USA) was used for the quantitative
determination of C-reactive protein in serum samples on a
fully automated IMMAGE
® Immunochemistry System
(Beckman Coulter). The IMMAGE
® Immunochemistry
System utilizes proven rate nephelometry methodologies
to provide specific, reproducible, quantitative protein
results. Serum lipid profiles and high-sensitivity C-
reactive protein were measured at baseline and at follow-
up.
Stent implantation procedure
Patients received BMS implantation for de novo lesions
in native coronary arteries having a reference diameter
between 2.5 and 4.0 mm. Stent implantation was
performed as previously described [13]. If residual
stenosis occurred after stent implantation, adjunctive
balloon angioplasty using a balloon with the same size as,
or a larger size than, the stent was performed. 
Quantitative coronary angiography (QCA)
Angiograms were analyzed with a validated QCA system
(Phillips H5000 or Allura DCI program; Philips Medical
Systems, Best, The Netherlands). Using the outer
diameter of a contrast-filled catheter as the calibration
standard, the minimal lumen diameter and reference
diameter were measured in diastolic frames from
orthogonal projections. 
In-stent restenosis
Patients were examined for in-stent restenosis during
the follow-up period. Angiographic restenosis was defined
as ≥ 50% stenosis in the stented segment, including peri-
stent reference segments within 5 mm from each stent
edge at follow-up, or at least a 50% loss of the original gain
in the minimal luminal diameter.
IVUS imaging protocol
IVUS examinations were performed at post-stenting
and at follow-up after intra-coronary administration of
300 µg nitroglycerin using a commercially available IVUS
system (Boston Scientific Corporation/SCIMed,
Minneapolis, MN, USA). This system allows for digital
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advanced distally to > 5 mm from the distal stent edges,
and imaging was performed using retrograde pullback at
an automatic pullback speed of 0.5 mm/sec proximally to
> 5 mm from the proximal stent edges. 
IVUS analysis
We performed IVUS analysis for the entire 5-mm
proximal and distal stent edge segments. Both proximal
and distal vessel segments were divided into 1-mm
subsegments and analyzed. Using planimetry software
(TapeMeasure; INDEC Systems Inc., Mountain View, CA,
USA), volumetric analysis for each subsegments was
performed. External elastic membrane (EEM) and lumen
areas were measured, and plaque plus media (P&M) area
(EEM-lumen area) and plaque burden (P&M area divided
by EEM area) were calculated from each cross-sectional
slice and were expressed as mean values (summation of
each measured values at 1-mm subsegments divided by
5). Area changes (∆ values) for each measurement were
calculated as follow-up minus post-stenting values. 
Statistical analysis
The SPSS version 15.0 (SPSS Inc., Chicago, IL, USA)
was used for all analyses. Continuous variables were
presented as the mean value ± 1 SD and compared using
paired or unpaired Student t tests or a nonparametric
Wilcoxon test if the normality assumption was violated.
Discrete variables were presented as percentages and
relative frequencies; comparisons were conducted using a
chi-square test or Fisher's exact test as appropriate. A p
value < 0.05 was considered statistically significant. 
RESULTS
Baseline characteristics and changes in serum lipid
profiles and high-sensitivity C-reactive protein
No significant differences in patient demographic
variables and medications, except for statin use, were
observed (Table 1). At follow-up, total cholesterol, low-
density lipoprotein-cholesterol, and triglyceride levels had
significantly decreased, and high-density lipoprotein-
cholesterol level had significantly increased, in the
simvastatin group as compared to the non-statin group.
High-sensitivity C-reactive protein levels were also
significantly lower in the simvastatin group as compared
to the non-statin group during follow-up (Table 2).
Table 1. Patient demographics and medications 
Variables Simvastatin Non-statin p value
(n = 132) (n = 64)
Age, yr 57 ± 15 58 ± 14 0.6
Male gender  92 (70) 47 (73) 0.6
Diabetes mellitus 32 (24) 16 (25) 0.9
Hypertension 74 (56) 32 (50) 0.4
Smoking 75 (57) 35 (55) 0.8
Clinical presentation 0.9
Stable angina 66 (50) 35 (55)
Unstable angina 45 (34) 20 (31)
NSTEMI 8 (6) 3 (5)
STEMI 13 (10) 6 (9)
Ejection fraction, % 63 ± 10 62 ± 10 0.9
Medications after stenting
Aspirin 125 (95) 60 (94) 0.8
Clopidogrel 121 (92) 59 (92) 0.9
Beta-blocker 106 (80) 49 (77) 0.5
ACE inhibitor 53 (40) 24 (38) 0.7
ARB 53 (40) 22 (34) 0.4
Follow-up duration, mon 9.6 ± 5.3 9.2 ± 4.5 0.4
Values are presented as mean ± SD or number (%).
NSTEMI, non-ST segment elevation myocardial infarction; STEMI, ST segment elevation myocardial infarction; ACE, angiotensin-converting
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Table 3. Coronary angiographic findings and procedural results 
Simvastatin Non-statin p value
(n = 132) (n = 64)
Target coronary arteries 0.5
Left anterior descending 99 (75) 45 (70)
Left circumflex 11 (8) 9 (14)
Right 22 (17) 10 (16)
Lesion type 0.5
B1 90 (68) 48 (75)
B2 17 (13) 8 (13)
C 25 (19) 8 (13)
Diseased vessel number 0.5
1 99 (75) 45 (70)
2 22 (17) 10 (16)
3 11 (8) 9 (14)
Stent size, mm 3.3 ± 0.5 3.2 ± 0.4 0.7
Stent length, mm 24 ± 12 22 ± 13 0.6
Adjunctive balloon angioplasty 77 (58)  32 (50) 0.3
Reference vessel size, mm 3.2 ± 0.8 3.1 ± 0.6 0.8
Pre-intervention MLD, mm 1.0 ± 0.5 1.1 ± 0.6 0.8
Post-intervention MLD, mm 3.1 ± 0.6 3.0 ± 0.4 0.8
Values are presented as mean ± SD or number (%).
MLD, minimal lumen diameter.
Table 2. Coronary angiographic characteristics
Baseline Follow-up p value
Total cholesterol, mg/dL
Simvastatin (n = 132) 180 ± 43 146 ± 40 < 0.001
Non-statin (n = 64) 173 ± 39 166 ± 34 0.5
p value 0.5 0.010
LDL-cholesterol, mg/dL
Simvastatin (n = 132) 120 ± 18 92 ± 30 < 0.001
Non-statin (n = 64) 117 ± 19 115 ± 28 0.8
p value 0.4 0.008
HDL-cholesterol, mg/dL
Simvastatin (n = 132) 38 ± 10 46 ± 13 < 0.001
Non-statin (n = 64) 40 ± 8 42 ± 16 0.6
p value 0.6 0.040
Triglyceride, mg/dL
Simvastatin (n = 132) 168 ± 469 132 ± 56 < 0.001
Non-statin (n = 64) 158 ± 48 146 ± 70 0.032
p value 0.3 0.046
High-sensitivity C-reactive protein, mg/dL
Simvastatin (n = 132) 1.3 ± 0.8 0.3 ± 0.3 < 0.001
Non-statin (n = 64) 1.1 ± 0.9 0.6 ± 0.8 0.011
p value 0.7 0.048
Values are presented as mean ± SD.
LDL, low-density lipoprotein; HDL, high-density lipoprotein.360 The Korean Journal of Internal Medicine Vol. 25, No. 4, December 2010
QCA results and restenosis
No significant difference in baseline coronary
angiographic findings and procedural results was
observed between the simvastatin group and the non-
statin group (Table 3). At follow-up, binary in-stent
restenosis was present in 16% of the simvastatin group
(21/132) and 20% of the non-statin group (13/64), and
repeat revascularization was performed in 14% of patients
in the simvastatin group (18/132) and 17% in the non-
statin group (11/64). However, these differences were not
significant (p= 0.3, p = 0.4, respectively).
IVUS results
IVUS follow-up was performed at a mean of 9.4 months
after stenting (range, 5 to 19 months). No stent edge
dissection was noted at post-stenting. Post-stenting peri-
stent reference segment minimum lumen sites were 3.1 ±
2.1 mm from their respective proximal stent edges and 2.9
± 1.9 mm from their respective distal stent edges. Overall,
within these sites, P&M area increased (proximal edge,
+0.5 ± 0.3 mm
2, p< 0.001; distal edge, +0.6 ± 0.4 mm
2,  p
< 0.001), and lumen area (proximal edge, -1.1 ± 0.5 mm
2,
p < 0.001; distal edge, -1.0 ± 0.4 mm
2, p < 0.001) and
EEM area (proximal edge, -0.6 ± 0.3 mm
2, p < 0.001;
distal edge, -0.4 ± 0.3 mm
2, p = 0.001) decreased from
post-stenting to follow-up. 
Using volumetric analysis, overall, mean P&M area
increased (∆ = +0.5 ± 0.5 mm
2, p < 0.001 at the proximal
edge and ∆ = +0.6 ± 0.4 mm
2, p < 0.001 at the distal
edge), and mean EEM (∆ = -0.4 ± 0.3 mm
2, p < 0.001 at
the proximal edge and ∆ = -0.3 ± 0.3 mm
2, p < 0.001 at
Table 4. Serial volumetric intravascular ultrasound analysis
Mean area  Simvastatin (n = 132)  Non-statin (n = 64)
Post-stenting Follow-up Post-stenting Follow-up
Proximal edge (n = 125) (n = 125) (n = 59) (n = 59)
EEM area, mm
2 15.8 ± 4.7 15.4 ± 4.6
a 15.5 ± 3.8 15.1 ± 4.3
a
Lumen area, mm
2 8.0 ± 3.3 7.3 ± 3.3
a 8.4 ± 4.1 7.3 ± 3.2
a
P&M area, mm
2 7.8 ± 2.4 8.1 ± 2.7
a 7.1 ± 3.2 7.8 ± 2.7
a
Plaque burden, % 49 ± 11 53 ± 13
a 46 ± 9 52 ± 13
a
Distal edge (n = 132) (n = 132) (n = 64) (n = 64)
EEM area, mm
2 14.0 ± 4.5 13.7 ± 5.6
a 13.8 ± 3.9 13.5 ± 4.5
a
Lumen area, mm
2 7.3 ± 3.0 6.6 ± 3.8
a 7.4 ± 3.0 6.4 ± 3.0
a
P&M area, mm
2 6.7 ± 2.5 7.1 ± 3.2
a 6.4 ± 2.5 7.1 ± 2.5
a
Plaque burden, % 48 ± 11 52 ± 11
a 46 ± 9 53 ± 14
a
Values are presented as mean ± SD.
EEM, external elastic membrane; P&M, plaque plus media.
aIndicates p value < 0.05 between post-stenting value and follow-up value. 
Figure 1. Serial area changes (follow-up minus post-stenting)
in mean plaque plus media (P&M), external elastic membrane
(EEM), and lumen areas according to the simvastatin therapy
at the proximal (A) and distal (B) peri-stent reference
segments. 
A
BJeong MH, et al. Statin at the peri-stent reference segments    361
the distal edge) and mean lumen area (∆ = -0.9 ± 0.5
mm
2, p < 0.001 at the proximal edge and ∆ = -0.9 ± 0.4
mm
2, p < 0.001 at the distal edge) decreased from post-
stenting to follow-up. 
For the proximal edge, mean P&M area significantly
increased, and mean lumen area and mean EEM area
significantly decreased at follow-up in both the
simvastatin and non-statin groups. However, no
significant differences were observed in changes in mean
P&M (simvastatin, +0.3 ± 0.2 mm
2 vs. non-statin, +0.7 ±
0.4 mm
2; p = 0.10), mean EEM (simvastatin, -0.4 ± 0.4
mm
2 vs. non-statin, -0.4 ± 0.3 mm
2; p = 1.0), and mean
lumen (simvastatin, -0.7 ± 0.4 mm
2 vs. non-statin, -1.1 ±
0.6 mm
2; p = 0.11) areas from post-stenting to follow-up
between the simvastatin and non-statin groups at the
proximal edge. For the distal edge, mean P&M area
significantly increased, and mean lumen area and mean
EEM area significantly decreased at follow-up in both the
simvastatin and non-statin groups. However, no
significant differences were observed in changes in mean
P&M (simvastatin, +0.4 ± 0.2 mm
2 vs. non-statin, +0.7 ±
0.3 mm
2; p = 0.18), mean EEM (simvastatin, -0.3 ± 0.3
mm
2 vs. non-statin, -0.3 ± 0.2 mm
2; p = 1.0), and mean
lumen (simvastatin, -0.7 ± 0.4 mm
2 vs. non-statin, -1.0 ±
0.6 mm
2; p = 0.19) areas from post-stenting to follow-up
between the simvastatin and non-simvastatin groups at
the distal edge (Table 4, Fig. 1). 
Although lumen loss within the first 3 mm from each
stent edge was primarily due to an increase in P&M area
rather than a change in EEM area, and lumen loss beyond
3 mm from each stent edge was due to a combination of
increased P&M area and decreased EEM area, no
significant differences were observed in changes in P&M,
EEM, and lumen area at every 1-mm subsegment between
the simvastatin and non-statin groups (Table 5).
In-stent restenosis occurred in 34 patients, including 14
stent edge in-stent restenosis (6 proximal edges and 8
distal edges). More significant lumen losses accompanied
by a greater increase in P&M area and a greater decrease
in EEM area occurred in the in-stent restenosis group as
compared to the no in-stent restenosis group from post-
stenting to follow-up: 1) P&M area (in-stent restenosis
group, +1.4 ± 0.9 mm
2 vs. no in-stent restenosis group,
+0.6 ± 0.4 mm
2; p < 0.001); 2) EEM area (in-stent
restenosis group, -0.9 ± 0.5 mm
2 vs. no in-stent restenosis
group, -0.3 ± 0.3 mm
2; p= 0.001); 3) lumen area (in-stent
restenosis group, -2.3 ± 1.4 mm
2 vs. no in-stent restenosis
group, -0.9 ± 0.5 mm
2; p < 0.001) No significant
differences were observed in changes in P&M, EEM, and
lumen areas according to the presence/absence of the use
of post-stenting adjunctive balloon angioplasty.
DISCUSSION
The results of this study demonstrate that usual dose-
simvastatin therapy does not affect disease progression
(plaque increase and lumen loss) and vascular remodeling
in peri-stent reference segments in patients undergoing
BMS implantation. 
Several IVUS studies have demonstrated the effects of
statins on plaque regression and vessel remodeling.
Suzuki et al. [14] reported that plaque area decreased by
12% in patients who received a statin as compared to 13%
increase in plaque area in those who did not receive a
statin. Additionally, vessel area was not enlarged in
Table 5. Changes in plaque plus media gain, lumen loss, and external elastic membrane are from the index to
follow-up intravascular ultrasound
Mean area  Proximal edge Distal edge
+5 +4 +3 +2 +1 -1 -2 -3 -4 -5
Simvastatin, mm
2 (n = 125) (n = 132)
EEM -0.6 -0.6 -0.5 -0.2 -0.1 -0.1 -0.2 -0.4 -0.4 -0.4
Lumen -0.7 -0.8 -0.8 -0.7 -0.6 -0.7 -0.7 -0.7 -0.7 -0.7
P&M +0.1 +0.2 +0.3 +0.5 +0.5 +0.6 +0.5 +0.3 +0.3 +0.3
Non-statin, mm
2 (n = 59) (n = 64)
EEM -0.6 -0.5 -0.6 -0.3 -0.1 -0.1 -0.1 -0.4 -0.5 -0.5
Lumen -1.1 -1.0 -1.4 -1.1 -1.0 -1.1 -1.0 -1.1 -1.0 -0.9
P&M +0.5 +0.5 +0.8 +0.8 +0.9 +1.0 +0.9 +0.7 +0.5 +0.4
Values are presented as mean ± SD.
EEM, external elastic membrane; P&M, plaque plus media.362 The Korean Journal of Internal Medicine Vol. 25, No. 4, December 2010
patients treated with a statin, but did show positive
remodeling in those who had plaque progression without
a statin. Jensen et al. [15] reported a significant reduction
(4.6%) in the lesion EEM area and in the lesion plaque
area (5.9%), but no change in reference measurements
after 12 months of simvastatin treatment. As a result, the
remodeling index was reduced by simvastatin from 1.01 ±
0.12 to 0.95 ± 0.09. Petronio et al. [16] reported that
therapy with 20 mg/day of simvastatin did not prevent
intimal hyperplasia or in-stent restenosis, but it promoted
atherosclerotic regression both at stented and nonstented
sites in patients with normocholesterolemia who
underwent coronary stenting. However, the main
objectives of previous studies [14-16] have not been to
assess the effects of statins on plaque regression and
vascular remodeling in peri-stent reference segments in
patients who underwent BMS implantation. In the
present study, we sought to assess the effects of a usual
dose of simvastatin (20 mg/day) on plaque regression and
vascular remodeling at peri-stent reference segments;
however, therapy with 20 mg/day of simvastatin did not
regress plaque at either the proximal or distal edges from
post-stenting to follow-up, and did not prevent in-stent
restenosis at a mean of 9.4 months of follow-up after
stenting. 
The response of adjacent reference segments not
covered by the stent is of major interest. Several studies
have demonstrated lumen loss adjacent to the stent edge
after BMS implantation. Hoffmann et al. [2] performed
serial IVUS analysis at the most normal-looking cross
section within a 10-mm segment proximal or distal to the
stent, another midway between this slice, and the
proximal or distal edge of the stent. In this study, the more
distant reference segments showed a greater degree of
remodeling (decrease in EEM area) than of tissue growth,
whereas anatomic sections sampled at a point closer to the
edge of the stent showed a similar amount of remodeling
and a greater degree of cellular proliferation (increase in
P&M area) as compared to the more distant reference
segments. Mudra et al. [3] reported no relevant
progression of the disease adjacent to the stent, despite a
considerable plaque burden within the reference
segments. Weissman et al. [4] analyzed reference
segments 10 mm proximal and distal to the stent at index
and follow-up. In this study, lumen loss in the adjacent
reference segments, which was most pronounced within
the first 2 mm of the stent edge, and lumen loss within 2
mm of the stent edge were due primarily to intimal
proliferation. In contrast, beyond 2 mm, negative
remodeling contributed more to lumen loss. In the
present study, lumen loss within the first 3 mm from each
stent edge was primarily due to an increase in P&M area
rather than a change in EEM area. Lumen loss beyond 3
mm from each stent edge was due to a combination of
increased P&M area and decreased EEM area.
The present study has some limitations. First, the
present study is retrospective and therefore subject to
limitations inherent to this type of clinical investigation.
Second, this single-center study included only a small
number of patients. Third, we did not assess changes in
EEM, lumen, and plaque areas that were more distant
from the stent edges, i.e., segments that were not affected
by the stent or balloon. Fourth, we did not compare the
effects of low-dose statin with moderate or high-dose
statin therapy on plaque regression and vascular
remodeling. Therefore, further prospective, randomized,
large-scale studies are needed. 
In conclusion, a usual dose of simvastatin does not
inhibit plaque progression and lumen loss and does not
affect vascular remodeling in peri-stent reference
segments in patients undergoing BMS implantation.
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